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ABSTRACT 
 
White matter hyperintensity volume (WMHV) is associated with greater risk of ischemic 
stroke, and discovery of genetic markers of increased WMHV may contribute to 
improved stroke risk prediction models, leading to novel stroke prevention strategies, 
especially in high-risk individuals. These genetic markers may have a greater effect in 
early-onset stroke patients due to their shorter exposure to environmental factors, or play 
a protective role in late-onset stroke patients. In a genome-wide study designed to 
discover single nucleotide polymorphisms (SNPs) associated with white matter 
hyperintensity burden in early- and late-onset stroke patients, approximately nine million 
SNPs were ascertained in 781 subjects, whose age, sex, WMHV, and history of 
hypertension, hyperlipidemia, and tobacco use were also determined. Association 
analyses in three subpopulations (patients with early-onset stroke, patients with average 
age of stroke onset, and patients with late-onset stroke) provided lists of SNPs associated 
with WMHV, and these SNPs were used to calculate genetic risk (GR) scores for each 
 v 
subject. Single-variable linear regression was used to identify which of the baseline 
characteristics were nominally significant, for inclusion in multivariable regression 
models with and without the effect contributed by the GR scores. We found that GR 
scores calculated using SNPs discovered in patients with early-onset stroke significantly 
predicted of white matter burden in patients with average age of stroke onset, and that GR 
scores calculated with a panel of SNPs discovered in patients with average age of stroke 
onset predicted WMHV in patients with late-onset stroke. Furthermore, our findings 
suggest a different genetic mechanism for increased WMHV in early-onset stroke 
patients. 
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INTRODUCTION 
 
Stroke is the fourth leading cause of death and a major cause of long-term 
disability in the United States (Roger et al., 2012). There are many known modifiable risk 
factors for stroke, including hypertension (HTN), heart rhythm abnormalities, tobacco 
use, hyperlipidemia (HLD), and diabetes, but these do not fully account for stroke risk 
(Goldstein et al., 2006). Therefore, heritability of stroke has been explored in twins, 
families, and animal models, which demonstrate a genetic contribution; however, the 
exact extent of this contribution remains unclear (Floßmann, Schulz, & Rothwell, 2004; 
Keum & Marchuk, 2009). Even though genetic risk factors are not modifiable, they can 
help inform prevention and treatment and also aid in more accurate prediction of a 
patient’s prognosis (Anderson, Biffi, Greenberg, & Rosand, 2010; Meschia, Worrall, & 
Rich, 2011). 
 
Stroke Etiology and Subtype Classification 
Any study of the genetics of stroke requires accurate phenotypic classification in 
order to correctly identify association between a particular genotype and stroke 
phenotype, as there are many subclasses of stroke (Figure 1) (Markus, 2011). The two 
main stroke subtypes are ischemic, in which the brain is deprived of oxygen due to 
obstruction of blood flow, and hemorrhagic, in which a blood vessel ruptures and blood 
accumulates inside the skull. Ischemic strokes are further subdivided by cause: an 
embolism, a thrombotic process in a large artery, various disease processes in small 
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vessels, other less common causes such as specific genetic conditions, or unknown causes 
(Dichgans, 2007). In contrast, hemorrhagic strokes are differentiated by location: 
subdural/epidural, subarachnoid, or intracerebral, which can be lobar or deep (Naidech, 
2011). 
 
 
Figure 1. Stroke subtypes by etiology. Stroke is divided into two main categories: 
ischemic and hemorrhagic; these can be further subclassified by cause, for ischemic 
stroke, or location, for hemorrhagic stroke. 
 
 
Many classification systems have been developed for diagnosis of ischemic 
stroke. The Oxfordshire Community Stroke Project (OCSP) system is primarily used in 
clinical settings to predict what area(s) of the brain is affected and the patient’s prognosis 
based on their symptoms (Bamford, Sandercock, Dennis, Warlow, & Burn, 1991). The 
Trial of Org 10172 in Acute Stroke Treatment (TOAST) system relies more heavily on 
computed tomography (CT) or magnetic resonance imaging (MRI) examination for 
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accurate diagnosis (Adams et al., 1993). Further, the Causative Classification of Stroke 
(CCS) system is a refinement of the TOAST system, utilizing a computer program to 
analyze medical chart information and brain scans to give a score of “evident,” 
“probable,” or “possible” for each cause (large artery atherosclerosis, cardio-aortic 
embolism, small artery occlusion, other, and undetermined) (Ay et al., 2007). Meanwhile, 
the ASCO Phenotypic Classification system grades each of atherosclerosis (A), small 
vessel disease (S), cardiac disease (C) and other causes (O) based on their presence and 
likelihood of contributing to the stroke, thereby formalizing some of the clinically used 
diagnosis procedures, codifying the level of diagnostic evidence used for grading, and 
accounting for patients whose stroke may have multiple contributing factors (Amarenco, 
Bogousslavsky, Caplan, Donnan, & Hennerici, 2009).  
In follow-up studies, intra- and inter-observer reliability of the OCSP and TOAST 
systems were found to be similar (Lindley et al., 1993; Meschia et al., 2006; Selvarajah et 
al., 2009). Lanfranconi and Markus demonstrated similar reliability between TOAST and 
CCS, while noting that CCS would be advantageous in multi-center studies where 
consistent subtyping was critical (2012). Marnane et al. reported that CCS resulted in 
fewer undetermined etiologies as compared with either the TOAST or ASCO systems, 
further supporting use of CCS (2010). Wolf, Sauer, Alonso, and Hennerici compared the 
TOAST and ASCO systems and found high inter-observer reliability for both systems as 
well as agreement between the two systems, noting that the ASCO system recorded more 
information than the TOAST system (2012). Thus, the computerized CCS and ASCO 
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systems are the most reliable for accurate phenotypic description of ischemic stroke by 
etiology.  
 
Stroke-Related Phenotypes 
There are a number of cerebrovascular phenotypes that may not be clinically 
apparent but can be detected on brain MRI. For example, cerebral microbleeds are 
generally silent (asymptomatic) and can either be precursors to hemorrhagic strokes or an 
indication of a small vessel disease process that could precede an ischemic stroke 
(Moran, Phan, & Srikanth, 2012). Similarly, MRI can detect silent brain infarcts, just as it 
can also reveal white matter hyperintensity (WMH) (Loitfelder, Seiler, Schwingenschuh, 
& Schmidt, 2012). 
WMH as seen on a CT/MRI brain scan is a rarefaction of white matter in the brain 
that is frequently observed in elderly individuals (Stewart, 2012). Cognitive impairment 
and neuropsychiatric disorders can accompany WMH, but lack of clinical abnormalities 
in the presence of WMH is also common (Meier et al., 2012; Sachdev, Chen, & Wen, 
2008). Its etiology is unknown, but vascular disease is suspected as an underlying cause, 
especially when the white matter changes are not periventricular (Figure 2) (Schmidt et 
al., 2011). WMH is an important intermediate phenotype to consider when studying 
stroke because it is highly correlated with increased incidence and poor clinical outcome 
after stroke, yet very little is known about it (Arsava et al., 2009; Inzitari, 2003). 
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Figure 2. White matter hyperintensities as seen on brain magnetic resonance 
imaging scan, axial T2 fluid-attenuated inversion recovery sequence. The arrows 
indicate (A) periventricular WMH and (B) deep WMH. 
 
 
Genetics of Stroke and WMH 
A number of genes that predispose individuals to stroke have been identified, and 
are thought to result in monogenic stroke disorders (Table 1). A prominent example is 
cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL), which is caused by mutations in the NOTCH3 gene 
and is inherited in an autosomal dominant (AD) manner (Joutel et al., 1996). When 
NOTCH3, a cell-surface receptor that plays a role in arterial development, is defective, 
the small vessels in the brain are particularly affected by the resulting stenosis which can 
lead to ischemic stroke (Pezzini, 2012). A mutation in GAL on the X-chromosome leads 
to Fabry’s disease due to an accumulation of glycosphingolipids in several organs, 
including the endothelium, which can cause large-artery and small vessel disease (Viana-
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Baptista, 2012). Sickle-cell disease, an autosomal recessive (AR) disease, frequently 
causes infarcts in small vessels and problems in partially occluded large arteries (Strouse, 
Lanzkron, & Urrutia, 2011). Homocystinuria, which is also inherited in an AR pattern, 
causes a host of issues including embolic or large-artery stroke due to thromboembolism 
or atherosclerosis, as well as lacunar stroke and stroke due to arterial dissection (Kalidas 
& Behrouz, 2008). There are also mitochondrial deoxyribonucleic acid (DNA) mutations 
that can cause myopathy, encephalopathy, lactic acidosis, and stroke-like episodes 
(MELAS) through a complex mechanism that likely involves microvasculature 
(Finsterer, 2012). Finally, connective tissue disorders such as Ehlers-Danlos syndrome 
type IV and Marfan syndrome adversely affect the endothelium and can cause arterial 
dissection, large-artery disease and small vessel disease (Ballabio, Bersano, Bresolin, & 
Candelise, 2007). 
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Table 1. Monogenic stroke disorders. 
 Mode of 
Inheritance Gene Stroke Mechanism 
CADASIL AD NOTCH3 Small vessel 
Fabry’s Disease X-linked GAL 
Large-artery 
Small vessel 
Sickle-cell disease AR HBB 
Large-artery 
Small vessel 
Hemodynamic insufficiency 
Homocystinuria AR CBS and others 
Large-artery 
Embolism 
Small vessel 
Arterial dissection 
MELAS Maternal Mitochondrial DNA Complex 
Ehlers-Danlos  
syndrome type IV 
AD COL3A1 Arterial dissection 
Marfan Syndrome AD FBN1 
Large-artery 
Small vessel 
Abbreviations: CADASIL = cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy; AD = autosomal dominant; AR = autosomal recessive; 
MELAS = myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. 
 
 
Some of these single-gene stroke disorders are fairly well characterized, while 
others are poorly understood, but almost nothing is known about the genetic factors that 
contribute to WMH. What we do know about the genetics of WMH comes primarily 
from twin studies (Reed et al., 2000). From these studies we have been able to estimate 
that the heritability of WMH is at least 40% and may be as high as 70%, which means 
that between 40% and 70% of the white matter disease burden found in the general 
population can be explained by genetic factors (Atwood et al., 2004). However, the usual 
approaches to finding disease-causing genes, such as linkage analysis within families 
with the disease, have only revealed rare mutations that only account for a small 
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proportion of the heritability, so we must turn to complex genetics to explain this large 
degree of heritability (Bouhouche et al., 2012). 
 
Novel Approaches to the Study of Cerebrovascular Disease Genetics 
A genome-wide association study (GWAS) aims to correlate genes or 
chromosomal loci to a disease phenotype. In the case of complex phenotypes, such as 
stroke, many genes contribute an effect, so the contribution of an individual gene can 
vary greatly. This contribution, or effect size, can either increase or decrease the 
likelihood of developing the phenotype. 
The greater the effect size of a genetic locus, the more clearly its association with 
the phenotype will appear. Specifying an intermediate phenotype that is more directly 
caused by genotypic factors will enrich the evident genetic contribution by the disease-
causing gene, in comparison to studying the gene’s association with the more complex 
and multi-factorial end-phenotype. Therefore, finding disease-causing alleles for WMH is 
more likely to yield strong results than correlating stroke with stroke-causing genes. 
Furthermore, genes that predispose an individual to WMH not only inform individuals’ 
increased stroke risk but also their increased risk for age-related cognitive decline and 
late-life depression (Aizenstein et al., 2011; Göthe et al., 2012). Thus, identification of 
genes related to WMH is postulated to enhance risk prediction models and potentially aid 
in discovery of novel targets for drug therapies to reduce the risk of stroke. 
One approach to address the difficulty of identifying disease-related genes with 
small effect sizes is to create a genetic risk score (GRS) that is calculated based on 
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multiple single nucleotide polymorphisms (SNPs) that are found to trend towards 
association with the phenotype of interest. In 2008, Kathiresan et al. generated a GRS 
based on eleven SNPs reported to have an association with either high-density lipoprotein 
or low-density lipoprotein, and found that an increased GRS predicted an earlier first 
cardiovascular event. Therefore, even though each of these SNPs explains at most two 
percent of the variance in lipid levels, combining them provides a measure that has 
clearer association with the phenotype. 
There are also a number of difficulties in studying the genetics of WMH in 
particular. For one, most genome-wide association (GWA) studies look for an association 
between presence of disease and disease-causing genes, but WMH is a continuous 
phenotype, meaning that it is not simply a question of whether or not it is present. Liguori 
et al. have developed a method to overcome this limitation: they used a regression model 
to investigate the association between a continuous phenotype (brain lesion volume) and 
candidate alleles in multiple sclerosis (2011). Second, because the effect contributed by 
each disease-causing gene is usually very small and requires a large amount of statistical 
power and therefore a large sample size to detect, a number of studies have turned to 
studying the extremes of the phenotype of interest; within the extremes, the effect size is 
expected to be greater, thereby reducing the power and sample size required for its 
detection (Cohen, Boerwinkle, Mosley, & Hobbs, 2006). Specifically, genes have a larger 
role in early-onset disease due to the decreased exposure to environmental factors; 
similarly, late-onset of disease is likely due to increased contribution of protective genetic 
loci (de Ridder et al., 2007; Shi et al., 2012). However, some questions remain with 
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regards to this approach, such as how to define the extremes of the phenotype, what 
population to replicate the results in, etc.  
In this paper, we examine the extremes of WMH phenotypes as related to the age 
of stroke onset (i.e. young adults with early-onset stroke and elderly individuals with late-
onset stroke) in order to discover genes that affect WMH burden and risk of stroke. 
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OBJECTIVES 
 
The genetics of stroke is a complicated field, with many well-characterized 
monogenic stroke disorders but an incomplete knowledge of the complex genetics 
underlying stroke. Many genetic loci have been associated with stroke, but they explain 
only a very small fraction of the variation in stroke and its related phenotype of WMH. 
Using a GWA approach, this study aimed to discover novel genetic loci that 
contribute to WMH severity in ischemic stroke patients at the extremes (early and late) of 
age-of-onset. We hypothesized that SNPs significantly associated with WMHV in early-
onset stroke patients would exhibit a stronger effect size in this population due to their 
decreased environmental exposure, and that SNPs significantly associated with WMH 
burden in late-onset strokes may have a protective effect against ischemic stroke.  
The ultimate goal of this study was to provide a foundation, including target SNPs 
for future replication efforts, for discovery of genetic loci that will aid future stroke 
genetics studies. 
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METHODS 
 
Study Population 
Study subjects were recruited as part of an ongoing longitudinal study of patients 
with ischemic stroke (Kelly et al., 2003). Consecutive patients greater than 18 years of 
age admitted to the Massachusetts General Hospital (MGH) Stroke Unit, including those 
admitted directly to the MGH emergency department (ED) or transferred to the ED from 
a referring hospital, were considered for enrollment. Patients underwent clinical 
evaluation by a neurologist and diagnostic imaging upon admission, and were diagnosed 
with ischemic stroke, defined as either (1) clinical stroke syndrome associated with 
radiographically proven infarct or (2) a fixed neurological deficit persisting for >24 hours 
that was consistent with a vascular event but without evidence of demyelination or 
nonvascular disease. Only patients with axial T2 Fluid-Attenuated Inversion Recovery 
(T2-FLAIR) sequences of quality suitable for quantification on cranial MRIs obtained 
<72 hours after admission for stroke were included in the analysis. Patients with 
symptoms of ischemic stroke related to specific vascular disorders (such as vasculitis, 
subacute bacterial endocarditis, fibromuscular dysplasia, vasospasm due to subarachnoid 
hemorrhage or cocaine abuse) or other known causes of WMH/stroke (such as 
CADASIL, MELAS, cranial radiotherapy, leukodystrophies, or mitochondrial disorders) 
were excluded. All participating subjects or their medical proxy provided informed 
consent for data collection, genotyping, and analysis of genetic data; the study was 
approved by the MGH Institutional Review Board. 
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Baseline characteristics were ascertained via direct patient and/or proxy interview 
and medical chart review and were coded following international guidelines (Pearson et 
al., 2002). Arterial HTN was defined as (1) at least two raised blood pressure 
measurements of either >140mmHg systolic or >90mmHg diastolic recorded on different 
days before onset, (2) physician diagnosis, or (3) use of antihypertensive medication. 
Similarly, HLD was determined with (1) previous serum cholesterol >200mg/dL, (2) 
serum triglyceride concentration >150mg/dL, (3) physician diagnosis, or (4) use of 
medication to control it. Finally, tobacco use was coded as never, past, or current. 
 
Neuroimaging Analysis 
MRI scans were acquired on 1.5 T Signa scanners (GE Medical Systems, 
Milwaukee, WI) and converted from Digital Imaging and Communications in Medicine 
(DICOM) format to Analyze format, using MRIcro software (Oxford, UK) (Rorden, 
1999; Rorden & Brett, 2000). Signal intensity thresholding was used to create a region-
of-interest map of supratentorial WMH in axial T2-FLAIR sequences, which was then 
manually edited as necessary to determine WMHV (Figure 3) (Chen et al., 2006). 
Corresponding diffusion weighted imaging sequences were aligned to exclude acute 
ischemia, edema, and chronic territorial infarcts, while possible confounding due to focal 
white matter damage from the index stroke was excluded by measuring only total 
WMHV from the hemisphere unaffected by the stroke unless the stroke resulted in an 
infratentorial infarct. Similarly, areas of signal change from previous infarctions were 
masked and not considered WMH. WMHV was normalized across the cohort by 
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multiplying by the ratio of the mean sagittal midline cross-sectional intracranial area 
(ICA) to the individual ICA, where ICA was a surrogate measure of the intracranial 
volume, according to a previously validated method (Nandigam et al., 2007). 
 
 
Figure 3. Magnetic resonance imaging-based volumetric analysis of white matter 
hyperintensity volume using MRIcro software. An axial T2-FLAIR sequence with 
WMH is presented in panel (A). In panel (B), a region-of-interest map has been drawn 
over the WMH on the right side. In panel (C), the hyperintensities on the scan have been 
automatically highlighted using signal intensity thresholding. Taking the intersection of 
the region-of-interest and the hyperintensities and then manually editing as necessary 
produces the final scan with the highlighted and quantified WMHV in panel (D). 
 
 
Genotyping: Quality Control and Imputation 
Genotyping was performed on the Genome-Wide Human SNP Array 6.0 
(Affymetrix), Illumina Human610-Quad v1.0 (Illumina), or HumanOmniExpress-12 v1.0 
(Illumina) platforms. SNPs were excluded from analysis per platform if (1) >5% of 
subjects were unable to be genotyped at that locus, (2) the minor allele frequency (MAF) 
was <1%, (3) the MAF was <5% and >1% subjects were unable to be genotyped, (4) they 
were significantly non-randomly missing with a p-value <1E-9, or (5) observed 
heterozygosity differed from predicted heterozygosity with a p-value <1E-6 (Wigginton, 
Cutler, & Abecasis, 2005). Subjects were excluded from analysis if (1) <80% of SNPs 
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genotyped were unable to be assessed, (2) their genotype-determined sex and reported 
sex did not agree, (3) they were related to another subject with better genotyping rate, or 
(4) principal component (PC) analysis with reference populations from the HapMap 
Project revealed non-European ancestry (Figure 4) (International HapMap Consortium, 
2003, 2005). Quantile-quantile plots of calculated-versus-expected p-values confirmed a 
minimal genomic inflation factor <1.10 (Figure 5). All genetic analysis was performed 
using PLINK v1.07 (Purcell, 2007; Purcell et al., 2007). Unobserved SNPs were imputed 
using Segmented HAPlotype Estimation and Imputation Tool (SHAPEIT), IMPUTE2 
and reference panels from the 1000 Genomes Project (Delaneau, Marchini, & Zagury, 
2012; Delaneau, Zagury, & Marchini, 2012, 2013; Howie & Marchini, 2007; Howie, 
Donnelly, & Marchini, 2009; The 1000 Genomes Project Consortium, 2010). GTOOL 
was used to transform imputed genotype data (Freeman & Marchini, 2007).  
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Figure 4. Principal component plot of MGH subjects and HapMap Project controls. 
HapMap Project Controls (represented by blue squares) were used to improve accuracy 
of PC calculations for MGH subjects, which were then classified as having European 
(represented by red circles) or non-European (represented by green diamonds) ancestry.  
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Figure 5. Quantile-quantile plot of expected and observed p-values in ischemic 
stroke cohort. Negative log transformed expected p-values (based on the number of 
SNPs in the analysis) are plotted on the x-axis, and negative log transformed observed p-
values are plotted on the y-axis. The genomic inflation factor is 1.022. 
 
 
Statistical Analysis 
Normalized WMHV (nWMHV) was natural log transformed for association 
analysis and linear regression. Association analysis of natural log transformed normalized 
WMHV (ln(nWMHV)) and genotype was performed within each platform and then 
meta-analyzed within three patient subpopulations: (1) Patients with Average Age of 
Stroke Onset (PAASO), (2) Patients with Late-Onset Stroke (PLOS), and (3) Patients 
with Early-Onset Stroke (PEOS), defined as individuals with stroke between the ages of 
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55-75 years, after the age of 75, and before the age of 55, respectively. The genome-wide 
significance level was Bonferroni-corrected for single SNP association testing 
(approximately nine million SNPs) and was therefore 5.6E-9.  
The association analysis results were meta-analyzed per population to produce 
three lists of SNPs that were able to be analyzed in >80% of the platforms and with p-
values for association <5E-4. Sixty-one additional SNPs associated with WMH in a 
previous study were added to each of the three lists, and SNPs that were in linkage 
disequilibrium with other SNPs that had lower p-values were pruned to produce the final 
lists of SNPs for calculating weighted (by effect size in the meta-analysis) and 
unweighted (all SNPs were given equal weight) genetic risk (GR) scores (Fornage et al., 
2011). Thus, the following four analyses were conducted: (1) the SNPs from the PAASO 
association analysis were used to calculate GR scores in PLOS and (2) PEOS, (3) the 
SNPs from the PLOS association analysis were used to calculate GR scores for PAASO, 
and (4) the SNPs from the PEOS association analysis were used to calculate GR scores in 
PAASO. GR scores using increasing number of SNPs were tested for association with 
ln(nWMHV), corrected for age, sex, PC1, and PC2, in order to find the GRS with 
maximum predictive value.  
The following baseline characteristics that have been reported to affect WMH 
burden in ischemic stroke patients were selected as covariates: age, sex, HTN, HLD, and 
history of tobacco use (Bousser, 2012). To determine which of these baseline 
characteristics to include in the multivariable linear regression models, single-variable 
linear regression of each baseline characteristic as the independent variable and 
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ln(nWMHV) as the dependent variable was performed. Multivariable linear regression 
models included the variables that had demonstrated nominal significance (p-value <0.2, 
two-sided) in the preliminary analysis. The unweighted and weighted GR scores were 
separately incorporated into the models to determine if the scores significantly improved 
the fit of the linear models (p-value <0.05, two-sided). Linear regression was performed 
using R (R Core Team, 2012). 
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RESULTS 
 
A total of 781 patients met inclusion criteria (Table 2). The age of the subjects 
ranged from 18.4 to 102.0 years of age; the mean age was 66.4 years, with a standard 
deviation (SD) of 14.5 years. Therefore, PEOS were defined to be subjects who had a 
stroke before the age of 55, which is approximately one SD below the mean and also a 
definition used clinically (Kittner & Singhal, 2013; von Sarnowski et al., 2013). 
Similarly, PLOS were defined as subjects who had a stroke after the age of 75 (Masotti, 
Ceccarelli, Forconi, & Cappelli, 2005). The majority of the cohort was male (61.8%), 
which was true for PAASO and PEOS, but not for PLOS, which was 46.8% male.  
The median nWMHV was 6.28 cm
3
, with an interquartile range of 2.78 cm
3
 to 
12.98 cm
3
. The mean ln(nWMHV) was 1.84, with a SD of 1.11. As expected, WMHV 
increased with age: the median nWMHV was 2.33 cm
3
 for PEOS, 6.28 cm
3
 for PAASO, 
and 11.78 cm
3
 for PLOS.  
A majority of the population had HTN (63.1%), though this was reversed in 
PEOS (37.6%). The proportion of subjects with HLD was similar between the overall 
group (42.1%) and PAASO and PLOS (47.4% and 43.5%), but PEOS had a lower 
incidence of HLD (29.8%). History of tobacco use was similar between PEOS and PLOS 
(54.7% and 54.8%) but was markedly greater in PAASO (72.4%). Missing data included 
HTN/HLD/tobacco status: 2 PLOS, 4 PAASO, and 2 PEOS had unknown HTN and HLD 
statuses, while 11 PLOS, 10 PAASO, and 6 PEOS had unknown tobacco statuses. 
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Table 2. Baseline characteristics of patients in ischemic stroke cohort.  
 
PEOS 
(n=181) 
PAASO 
(n=351) 
PLOS 
(n=249) 
All 
(n=781) 
Age (years) — mean ± SD 46.3 ± 7.4  65.6 ± 5.8  82.3 ± 5.3  66.4 ± 14.5  
Male Sex — number of subjects (%) 122 (67.4) 245 (69.6) 116 (46.8) 483 (61.8) 
nWMHV (cm
3
) 
median 
interquartile range 
2.33 
1.55 - 4.18 
6.28 
(3.22, 12.42) 
11.78 
(6.18, 23.74) 
6.28 
(2.78, 12.98) 
ln(nWMHV) — mean ± SD 0.94 ± 0.88  1.87 ± 0.99  2.47 ± 0.97  1.84 ± 1.11  
HTN — number of subjects (%) 68 (37.6) 232 (65.9) 193 (77.8) 493 (63.1) 
HLD — number of subjects (%) 54 (29.8) 167 (47.4) 108 (43.5) 329 (42.1) 
Tobacco — number of subjects (%) 99 (54.7) 255 (72.4) 136 (54.8) 490 (62.7) 
Abbreviations: PEOS = patients with early-onset stroke, PAASO = patients with average 
age of stroke onset, PLOS = patients with late-onset stroke, SD = standard deviation, 
nWMHV = normalized white matter hyperintensity volume, ln(nWMHV) = natural log 
transformed normalized white matter hyperintensity volume, HTN = hypertension, HLD 
= hyperlipidemia. 
 
 
No SNPs reached genome-wide significance (p-value <5.6E-9) in any of the three 
meta-analyses after discarding SNPs analyzed in fewer than 80% of the platforms 
(Figures 6-8). Using SNPs with p-value <5E-4 from the PAASO meta-analysis and 
previously discovered SNPs, we found that an unweighted GRS generated from the top 9 
SNPs and a weighted GRS of the top 8 SNPs best predicted the phenotype in PLOS 
(Figure 9A & 9B). The unweighted/weighted scores calculated with 50 SNPs from the 
PAASO association analysis corresponded to the most correlation with ln(nWMHV) in 
PEOS (Figure 9C & 9D). The GR scores derived for PAASO using the 8 most significant 
SNPs from the PLOS meta-analysis were more correlated to the phenotype as compared 
with GR scores calculated with more or fewer SNPs (Figure 9E & 9F). Finally, using the 
14 most significant SNPs from the PEOS meta-analysis generated the best unweighted 
and weighted scores in PAASO (Figure 9G & 9H). 
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Figure 6. Manhattan plot of p-values from meta-analysis of single nucleotide 
polymorphisms from patients with average age of stroke onset. These p-values are 
derived from the meta-analysis of the association analyses of SNPs and ln(nWMHV) in 
patients with average age stroke onset (n=351), negative log transformed, and plotted 
against the base pair position on the x-axis. No SNPs reached the genome-wide 
significance level of 5.6E-9 indicated by the red significance line; the blue significance 
line represents the cutoff for SNPs included in the GRS calculations (p<5E-4, 1341 
SNPs). 
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Figure 7. Manhattan plot of p-values from meta-analysis of single nucleotide 
polymorphisms from patients with late-onset stroke. These p-values are derived from 
the meta-analysis of the association analyses of SNPs and ln(nWMHV) in patients with 
late-onset stroke (n=249), negative log transformed, and plotted against the base pair 
position on the x-axis. No SNPs reached the genome-wide significance level of 5.6E-9 
indicated by the red significance line; the blue significance line represents the cutoff for 
SNPs included in the GRS calculations (p<5E-4, 2059 SNPs). 
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Figure 8. Manhattan plot of p-values from meta-analysis of single nucleotide 
polymorphisms from patients with early-onset stroke. These p-values are derived 
from the meta-analysis of the association analyses of SNPs and ln(nWMHV) in patients 
with early-onset stroke (n=181), negative log transformed, and plotted against the base 
pair position on the x-axis. No SNPs reached the genome-wide significance level of 5.6E-
9 indicated by the red significance line; the blue significance line represents the cutoff for 
SNPs included in the GRS calculations (p<5E-4, 2222 SNPs). 
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Figure 9. P-value distribution for genetic risk scores calculated with increasing 
numbers of single nucleotide polymorphisms. The x-axis is the number of SNPs used 
to calculate the score, plotted against the negative logarithm of the score’s p-value for 
correlation with ln(nWMHV), corrected for age, sex, PC1, and PC2. (A) and (B) are the 
unweighted and weighted scores in PLOS, respectively, while (C) and (D) are the 
unweighted and weighted scores in PEOS, respectively, calculated using SNPs from the 
PAASO association analysis; (E) and (F) are the unweighted and weighted scores, 
respectively, in PAASO using SNPs from PLOS; (G) and (H) are the unweighted and 
weighted scores, respectively, in PAASO using SNPs from PEOS. The first maximum in 
each of these plots occurred at 9 SNPs, 8 SNPs, 50 SNPs, 50 SNPs, 8 SNPs, 8 SNPs, 14 
SNPs, and 14 SNPs, respectively. 
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Single-variable linear regression of the predictor variables revealed a nominally 
significant (p-value <0.2) effect of age, HLD status, PC1, PC2, and PC3 on ln(nWMHV) 
in PAASO (Table 3). In PLOS, sex, HLD status, history of tobacco use, PC1, PC2, and 
PC3 reached nominal significant association with ln(nWMHV), while in PEOS, only age, 
HTN status, and history of tobacco use were nominally significant.  
 
Table 3. Independent predictors of natural log transformed normalized white 
matter hyperintensity volume in ischemic stroke cohort and subpopulations.  
 All PAASO PLOS PEOS 
 Effect 
Size 
P-value 
Effect 
Size 
P-value 
Effect 
Size 
P-value 
Effect 
Size 
P-value 
Age 0.040 < 2E-16† 0.051 1.81E-8† 0.013 0.288 0.019 0.028† 
Male sex -0.203 0.013† 0.050 0.662 -0.265 0.032† 0.168 0.23 
HTN 0.476 7.23E-9†
 
0.130 0.247 0.008 0.958 0.245 0.073† 
HLD -0.022 0.783 -0.212 0.045† -0.215 0.086† 0.124 0.391 
Tobacco 0.032 0.707 -0.025 0.838 -0.205 0.11† 0.366 6.58E-3† 
PC1 -8.406 0.389 -22.075 0.105† -45.972 7.28E-4† 0.243 0.990 
PC2 19.205 0.28 42.593 0.059† 49.972 0.070† 41.689 0.228 
PC3 2.582 0.371 8.436 0.035† 12.772 9.46E-4† 7.699 0.25 
PC4 -30.011 0.085† -11.464 0.607 11.978 0.65 -25.691 0.454 
Abbreviations: PAASO = patients with average age stroke onset, PLOS = patients with 
late-onset stroke, PEOS = patients with early-onset stroke, HTN = hypertension, HLD = 
hyperlipidemia, PC = principal component. 
†P-values reached nominal significance (<0.2). 
 
 
Integration of the unweighted GRS calculated using the 9 most significant SNPs 
from the PAASO association analysis demonstrated significant association with the 
phenotype in PLOS (p-value = 0.030), and integration of the weighted GRS calculated 
using the 8 most significant SNPs demonstrated significant association  as well (p-value 
= 0.035) (Table 4). Male sex was a significant predictor of ln(nWMHV) in PLOS, with or 
without the GRS. The GR scores derived for PEOS from the top 50 SNPs from the 
PAASO meta-analysis were not significantly correlated with WMH burden, though they 
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did trend towards significance with p-values of 0.106 for the unweighted GRS and 0.146 
for the weighted GRS (Table 5). History of tobacco use was significantly associated with 
the phenotype in PEOS throughout. 
The GR scores calculated in PAASO using SNPs from the PLOS association 
analysis trended toward significant association with the phenotype (unweighted GRS p-
value = 0.103, weighted GRS p-value = 0.104), while age was significantly correlated in 
all three models (Table 6). Both unweighted and weighted GR scores derived from the 
PEOS association analysis demonstrated significant association with ln(nWMHV) in 
PAASO (Table 7). Age was a significant predictor throughout, and HLD reached 
significance in the models with either the unweighted or the weighted GRS. 
 
Table 4. Multivariable linear regression model of natural log transformed 
normalized white matter hyperintensity volume in patients with late-onset stroke 
including genetic risk scores. The unweighted GRS was calculated using the 9 most 
significant SNPs from the PAASO association analysis; the weighted GRS was 
calculated using the 8 most significant SNPs. 
 
Model 
Model with 
Unweighted GRS 
Model with 
Weighted GRS 
 Effect Size P-value Effect Size P-value Effect Size P-value 
Intercept 1.859 8.5E-3* 0.881 0.287 0.585 0.525 
Male sex -0.320 0.019* -0.321 0.017* -0.335 0.013* 
HLD -0.162 0.196 -0.135 0.278 -0.142 0.255 
Tobacco  -0.082 0.541 -0.058 0.666 -0.049 0.715 
PC1 -44.283 0.154 -40.587 0.188 -42.369 0.169 
PC2 10.189 0.772 6.175 0.859 7.716 0.825 
PC3 2.899 0.746 3.411 0.701 2.903 0.744 
GRS   0.225 0.030* 0.440 0.035* 
Abbreviations: GRS = genetic risk score, SNPs = single nucleotide polymorphisms, 
PAASO = patients with average age of stroke onset, HLD = hyperlipidemia, PC = 
principal component. 
*P-values reached significance (<0.05). 
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Table 5. Multivariable linear regression model of natural log transformed 
normalized white matter hyperintensity volume in patients with early-onset stroke 
including genetic risk scores. Unweighted and weighted GR scores were calculated 
using the 50 SNPs most significantly associated with ln(nWMHV) in PAASO. 
 
Model 
Model with 
Unweighted GRS 
Model with 
Weighted GRS 
 Effect Size P-value Effect Size P-value Effect Size P-value 
Intercept 0.022 0.958 1.488 0.136 1.662 0.167 
Age 0.015 0.099 0.016 0.074 0.016 0.080 
HTN 0.128 0.362 0.145 0.300 0.147 0.296 
Tobacco 0.336 0.013* 0.323 0.016* 0.326 0.015* 
GRS   -0.072 0.106 -0.114 0.146 
Abbreviations: GR = genetic risk, SNPs = single nucleotide polymorphisms, 
ln(nWMHV) = natural log transformed normalized white matter hyperintensity volume, 
PAASO = patients with average age of stroke onset, GRS = genetic risk score, HTN = 
hypertension. 
*P-values reached significance (<0.05). 
 
 
 
Table 6. Multivariable linear regression model of natural log transformed 
normalized white matter hyperintensity volume in patients with average age of 
stroke onset including genetic risk scores calculated with genetic loci from 
association analysis in patients with late-onset stroke. Unweighted and weighted GR 
scores were calculated using a panel of the 8 SNPs most significantly associated with 
ln(nWMHV) in PLOS. 
 
Model 
Model with 
Unweighted GRS 
Model with 
Weighted GRS 
 Effect Size P-value Effect Size P-value Effect Size P-value 
Intercept -1.246 0.099 -1.804 0.030* -2.308 0.021* 
Age 0.050 1.86E-8* 0.050 1.96E-8* 0.050 1.76E-8*
 
HLD -0.193 0.058 -0.186 0.066 -0.192 0.058 
PC1 -0.741 0.976 0.888 0.971 2.135 0.931 
PC2 22.852 0.345 22.827 0.344 22.196 0.358 
PC3 6.189 0.422 6.533 0.396 6.841 0.374 
GRS   0.142 0.103 0.196 0.104 
Abbreviations: GR = genetic risk, SNPs = single nucleotide polymorphisms, 
ln(nWMHV) = natural log transformed normalized white matter hyperintensity volume, 
PLOS = patients with late-onset stroke, GRS = genetic risk score, HLD = hyperlipidemia, 
PC = principal component. 
*P-values reached significance (<0.05). 
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Table 7. Multivariable linear regression model of natural log transformed 
normalized white matter hyperintensity volume in patients with average age of 
stroke onset including genetic risk scores calculated with genetic loci from 
association analysis in patients with early-onset stroke. Unweighted and weighted GR 
scores were calculated from the top 14 SNPs associated with ln(nWMHV) in PEOS. 
 
Model 
Model with 
Unweighted GRS 
Model with 
Weighted GRS 
 Effect Size P-value Effect Size P-value Effect Size P-value 
Intercept -1.246 0.099 -1.040 0.168 -1.045 0.168 
Age 0.050 1.86E-8* 0.049 3.7E-8*
 
0.049 3.87E-8*
 
HLD -0.193 0.058 -0.208 0.040* -0.207 0.041* 
PC1 -0.741 0.976 -2.138 0.930 -1.497 0.951 
PC2 22.852 0.345 24.600 0.306 26.245 0.277 
PC3 6.189 0.422 6.812 0.374 6.899 0.369 
GRS   -0.298 0.015* -0.205 0.040* 
Abbreviations: GR = genetic risk, SNPs = single nucleotide polymorphisms, 
ln(nWMHV) = natural log transformed normalized white matter hyperintensity volume, 
PEOS = patients with early-onset stroke, GRS = genetic risk score, HLD = 
hyperlipidemia, PC = principal component. 
*P-values reached significance (<0.05). 
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DISCUSSION 
 
In this paper we report the results of a GWAS of WMH in ischemic stroke 
patients, which explored the age of stroke onset in order to improve SNP discovery and to 
derive a GRS to enhance prediction modeling. The GRS derived from the most 
significant SNPs from PAASO was significantly correlated with ln(nWMHV) in PLOS, 
and the GRS built with the most significant SNPs from PEOS predicted WMH burden in 
PAASO. 
Single-variable linear regression of baseline characteristics to predict 
ln(nWMHV) demonstrated a statistically significant protective effect of male sex in the 
overall cohort and PLOS. This effect may be explained in part by the trend of females 
reaching an older age before experiencing a stroke (as demonstrated by the greater 
proportion of female PLOS, in contrast to the overall cohort and other subpopulations). 
Therefore, female PLOS may appear to have greater WMH burden on average than their 
male counterparts simply due to their increased age, which is known to be a predictor of 
WMHV.  
Furthermore, HTN was noted to have a reduced effect size and greatly reduced 
significance as a predictor of WMH burden in PLOS. This may potentially be explained 
by the fact that a large proportion of PLOS have HTN, causing loss of correlation with 
WMHV. This may also explain the notable correlation of HTN with WMHV in PEOS 
demonstrated in the single-variable analysis. 
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The apparent protective effect of HLD with respect to ischemic stroke 
demonstrated in the single-variable and multivariable analyses in PAASO and PLOS is in 
agreement with other publications in the literature; these authors speculate that the 
protective effect may be explained in part by the important role of cholesterol in nervous 
system development and synapse formation and maintenance (Arboix et al., 2007; 
Jimenez-Conde et al., 2010).  Beghi et al. reported a protective effect of HLD for 
incidence of intracerebral hemorrhage and commented that the relationship between lipid 
levels and risk of ischemic or hemorrhagic stroke is complex (2011). In 2007, Roquer et 
al. reported a protective effect of HLD on mortality in acute ischemic stroke patients, and 
this may be explained by increased anoxia tolerance resulting from hypercholesterolemia 
(Xi et al., 2006). This protective effect of HLD should be investigated in future studies 
focused on lipid levels and their relation to stroke risk.  
The GR scores calculated using SNPs from PAASO demonstrated a significant 
association with ln(nWMHV) in PLOS, which will require replication in follow-up 
studies. As discussed above, the risk factor of male sex is likely highly intertwined with 
age in PLOS, and more stratified investigation of the subpopulation is necessary to 
correctly interpret the independent and interaction effects of age and sex on WMH 
burden in this age group. 
The unweighted/weighted GRS using the top 50 SNPs from PAASO did not result 
in a significant association with the PEOS phenotype, but trended toward significance. 
This could be due to a combination of lack of power due to the small number of PEOS 
and/or less of an effect from the SNPs that increase WMH burden in most of the 
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population; that is, PEOS may have earlier incidence of stroke and the associated 
increased WMH burden compared to others of their age cohort due largely to SNPs that 
are responsible specifically for early-onset increase in WMHV, and therefore are affected 
less by the non-age-specific SNPs. 
The top 8 SNPs from the PLOS association analysis also did not result in a GRS 
that reached significance for association with ln(nWMHV), but the GRS did trend toward 
significance. Again, this may have been due to lack of power and would be improved in a 
larger population. In contrast, the top 14 SNPs from the PEOS association analysis had 
significant predictive value in PAASO and should be verified in future replication 
studies. Age remained significant throughout the PAASO phenotype prediction models, 
which may be attributed to the range of ages in the subpopulation. HLD trended towards 
significance in the PAASO multivariable models, but reached significance with the 
integration of GR scores calculated using SNPs from PEOS, which could suggest a 
possible gene-environment interaction. 
History of tobacco use may also represent a gene-environment interaction effect 
in these data. The effect size of tobacco use is consistent and significant throughout the 
PEOS regression models, which is consistent with smoking’s effect on DNA expression, 
possibly via DNA methylation mechanisms (Chassanidis et al., 2012; Siedlinski et al., 
2012). Performing association analysis between genotype and ln(nWMHV) corrected for 
history of tobacco use in PEOS may yield different SNPs whose effects are potentially 
less dependent on mediation via smoking, and therefore may demonstrate a different 
direction of effect in other populations. 
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The negative direction of effect of SNPs discovered in PAASO and then 
integrated into a prediction model for PEOS and of SNPs discovered in PEOS used to 
predict WMHV in PAASO suggests that the SNPs responsible for increasing WMH 
burden in the two populations are distinct. Future GWA studies of ischemic stroke may 
need to analyze these two groups separately or risk failing to detect significant SNPs due 
to the heterogeneity of the study population. 
There are a number of limitations in this study. First, genotyping errors could 
have resulted in false associations or limited our ability to detect true associations 
between SNPs and our phenotype of interest. Incorrectly genotyped SNPs could also 
have resulted in errors during the imputation process. However, we believe that our 
threshold for calling a SNP is similar to that of other studies, and errors were avoided as 
best as possible within the limitations of current genotyping technology. Second, our 
subjects were genotyped on three different platforms, which could introduce an element 
of heterogeneity into the population. To correct for differences in the platforms, all 
subjects were imputed so that there was significant overlap in ascertained SNPs between 
subjects genotyped on different platforms, and association analyses were performed per 
platform to maintain consistency within the platform and then meta-analyzed. Third, 
phenotyping could have been more complete and detailed. Not all subjects’ HTN, HLD, 
or tobacco statuses were known, but these subjects were excluded from the corresponding 
single-variable/multivariable regression analyses. Also, history of tobacco use could be 
more ideally described with additional characteristics such as age at first exposure, 
duration of tobacco use, degree of tobacco use (e.g. number of cigarettes smoked per 
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day), and more. Unfortunately, such data are difficult to collect accurately, with a 
potential for recall bias by the subject or their proxy. Thus, dichotomizing patients as 
having a history of tobacco use or having no history of tobacco use allowed for 
simplification of the analysis, albeit at a possible loss of information that might have been 
obtained from use of the more detailed variable. Lastly, classification of the study 
population into three subpopulations reduced our power to detect significant gene effects, 
but the increase in effect size afforded by this stratified analysis seemed to mitigate that 
reduction in power. 
An advantage of our study was the volumetric analysis of WMH, which allows 
for linear regression and greater power to detect association than in a logistic regression 
model. This cohort is also the largest study population of ischemic stroke patients 
analyzed in a GWAS for WMH.  
In conclusion, we found a significant association between a GRS derived from 
SNPs discovered in PAASO and WMH burden in PLOS, as well as between a GRS 
calculated in PAASO from a panel of the 14 SNPs most significantly associated with 
ln(nWMHV) in PEOS; the increase in WMHV conferred by these GR scores could not be 
explained by traditional vascular risk factors. The effect of these SNPs will need 
verification in future replication studies, and may be candidates for targeted preventative 
therapies or treatments. Furthermore, our findings suggest that future GWA studies may 
need to analyze early-onset ischemic stroke patients independently of other stoke 
subjects, as there may be a different genetic mechanism affecting WMHV in these 
patients. 
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